|Day Low/High||8.68 / 8.89|
|52 Wk Low/High||11.45 / 46.17|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARCI, GRC, HDNG, PLPC Downgrades: AFI, CXW, DEL, HBMD, INSY, JCAP, MET, NGVC, PLT, SATS, STRL, UHS, VRTV, WP Initiations: PI, VRS Read on to get TheStreet Quant Ratings' detailed report:
Jim Cramer says the calendar and the momentum holders are coalescing to produce selling. Here's what investors should do about it.
In trading on Friday, shares of Insys Therapeutics Inc crossed below their 200 day moving average of $11.34, changing hands as low as $11.17 per share. Insys Therapeutics Inc shares are currently trading off about 1.6% on the day.
Investors in Insys Therapeutics Inc saw new options begin trading today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new September 15th contracts and identified one put and one call contract of particular interest.
Alder BioPharmaceuticals, Aralez Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on June 27.
Investors in Insys Therapeutics Inc saw new options begin trading this week, for the February 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.
The FDA requested Endo to remove its opioid pain medication from the market, expressing concern that the "benefits of the drug may no longer outweigh its risks."
Although a cannabis ETF launched in April, investors are still likely to find more value in buying individual stocks in the sector, according to traders.
Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
In recent trading, shares of Insys Therapeutics Inc have crossed above the average analyst 12-month target price of $14.00, changing hands for $14.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Launch Planned for August 2017
The most recent short interest data was recently released for the 04/28/2017 settlement date, and Insys Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 20.51 "days to cover" versus the median component at 4.80. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Jim Cramer is bullish on Raytheon, Celgene, and Orbital ATK; he's bearish on CenturyLink and Pennsylvania Real Estate Investments.
Jim Cramer says Home Depot, AMD and Alphabet are three examples of winners that have been so hard to stay in that he think you can still buy.
Here are Wednesday's top research calls, including downgrades for Allergan and General Dynamics, and upgrades for Coach and Occidental Petroleum.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.